酵素阻害剤の世界市場 - 2024年～2032年

酵素阻害剤の世界市場は、2023年に1,827億7,000万米ドルに達し、2032年には2,565億3,000万米ドルに達すると予測され、予測期間2024年のCAGRは3.9%で成長します。

酵素阻害剤は酵素に結合し、その活性を阻害または低下させる製品です。そうすることで、酵素阻害剤は体内の生化学反応を調節または変化させます。これらの酵素阻害剤は可逆的または不可逆的に酵素に結合します。可逆的阻害剤は一時的に結合し、一定期間活性を低下させます。一方、非可逆的阻害剤は酵素と永久的な結合を形成し、酵素を効果的に不活性化します。新しい酵素が形成されない限り、酵素の生物学的活性は回復しないです。

生物学的活性を変化させる能力があるため、これらの阻害剤は、高血圧、糖尿病、感染症、がんなどの病態の管理など、多様な治療用途があります。

市場力学：

促進要因と抑制要因

慢性疾患の増加

酵素阻害剤の主な用途は、糖尿病、がん、心血管疾患、呼吸器疾患、肥満、神経変性疾患などの慢性疾患です。人口の高齢化、座りがちなライフスタイル、不健康な食習慣、環境条件の悪化など、いくつかの要因により、これらの慢性疾患の発生率や有病率が上昇しています。

注：心血管疾患と糖尿病の統計は2023年の総症例数、がんの症例数は2022年の5年有病率、GLOBOCANより引用

酵素阻害剤は、疾患の病態に関与する酵素を特異的に標的とし修飾することにより、これらの疾患の管理において重要な役割を果たしています。これらの慢性疾患の有病率が上昇するにつれて、酵素阻害剤の需要も増加し、将来の市場成長を促進すると予想されます。

市場の飽和とジェネリック医薬品とブランドの競合の激化は、市場の成長を大きく阻害する可能性があります。

酵素阻害薬が多く処方されているいくつかの治療領域では、ジェネリックメーカーとブランドメーカーの間で大きな競争が起きています。新規参入業者の脅威となる可能性があります。ジェネリック医薬品が飽和状態にある市場にブランド医薬品を投入するのはリスクが高く、採用率が低くなる可能性があります。

例えば、高血圧症は、酵素阻害剤が主要な用途を見出す最も一般的な疾患です。この薬剤クラスはアンジオテンシン変換酵素（ACE）阻害薬と呼ばれ、リシノプリル、カプトプリル、エナロプリルなどがあります。これらの薬剤は、世界中の複数のジェネリックメーカーから広く販売されています。これらのジェネリック医薬品のイントロダクションより、ゼストリル（リシノプリル）やバソテック（エナラプリル）などのブランド医薬品の売上や採用率は大幅に減少しています。このような飽和市場では、新しいブランド医薬品に対する需要は低く、そのため成長率が抑制されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疾患の蔓延
    • 治療用途の拡大
  • 抑制要因
    • 市場の飽和とジェネリックとブランドの激しい競合
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• パイプライン分析
• 疫学
• 特許分析
• 規制分析

第6章 酵素の種類別

• アンジオテンシン変換酵素（ACE）阻害剤
• シクロオキシゲナーゼ（COX）阻害剤
• プロトンポンプ阻害剤
• プロテアーゼ阻害剤
• ベータラクタマーゼ阻害剤
• HMG-CoA還元酵素阻害剤
• ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
• ホスホジエステラーゼ（PDE）阻害剤
• チロシンキナーゼ阻害剤
• モノアミン酸化酵素（MAO）阻害剤
• アセチルコリンエステラーゼ（AChE）阻害剤
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤
• その他

第7章 薬剤クラス別

• 抗炎症薬
• 抗がん剤
• 抗生物質
• 抗ウィルス薬
• 降圧剤
• 抗糖尿病薬
• 胃腸薬
• 心臓血管薬
• 神経薬
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 酵素タイプのポートフォリオと説明
  • 財務概要
  • 主な発展
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• AbbVie Inc.
• Sanofi
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company.

第12章 付録

The global enzyme inhibitor market reached US$182.77 billion in 2023 and is expected to reach US$256.53 billion by 2032, growing at a CAGR of 3.9% during the forecast period 2024-2032.

An enzyme inhibitor is a product that binds to an enzyme and blocks or reduces its activity. By doing so, the enzyme inhibitor regulates or alters the biochemical reactions within the body. These enzyme inhibitors bind to the enzyme either reversibly or irreversibly. Reversible inhibitors bind temporarily and reduce their activity for a specific period. Irreversible inhibitors, on the other hand, form a permanent bond with the enzyme, effectively deactivating it. The biological activity of the enzyme will not be regained unless a new enzyme is formed.

Due to their ability to modify biological activity, these inhibitors have diverse therapeutic applications, including managing conditions like hypertension, diabetes, infectious diseases, and cancer.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The major applications of enzyme inhibitors are in chronic diseases such as diabetes, cancer, cardiovascular diseases, respiratory illnesses, obesity, neurodegenerative disorders, etc. Due to several factors such as the aging population, sedentary lifestyle, unhealthy eating habits, and worsening environmental conditions, there is a rising incidence and prevalence of these chronic conditions.

Note: The cardiovascular diseases and diabetes statistics represent total cases in 2023, and the cancer cases represent 5-year prevalence cases in 2022, adopted from GLOBOCAN

Enzyme inhibitors play a crucial role in the management of these diseases by specifically targeting and modifying the enzymes involved in the disease pathology. As the prevalence of these chronic diseases rises, the demand for enzyme inhibitors is expected to rise, propelling the market's growth in the future.

Market saturation and high generic and brand competition can significantly hinder enzyme inhibitor market growth.

In several therapy areas where enzyme inhibitors are highly prescribed, there is a huge competition between generic manufacturers and brand manufacturers. This can pose a significant threat to new entrants, as the potential for revenue generation is quite low. Launching a branded drug in a generic saturated market is risky and may lead to a low adoption rate.

For instance, hypertension is the most common condition where enzyme inhibitor find their major application. The drug class is termed angiotensin-converting enzyme (ACE) inhibitors and the drugs include lisinopril, captopril, enalopril, etc. These drugs are widely available from several generic manufacturers across the globe. The introduction of these generic versions has greatly reduced the sales and adoption rate for branded drugs such as Zestril (Lisinopril) and Vasotec (Enalapril). In such a saturated market, the demand for newer branded drugs is low, hence restraining their growth rate.

Segment Analysis

The global Enzyme inhibitor market is segmented based on enzyme type, drug class, distribution channel, and region.

Poly(ADP-ribose) Polymerase (PARP) Inhibitors in the enzyme type segment are expected to grow with the highest CAGR in the forecast period.

Poly(ADP-ribose) Polymerase (PARP) is a family of enzymes that play a crucial role in various cellular processes at the genetic level. These enzymes are the key mediators in cellular stress responses, DNA repair, cell proliferation, and cellular death. PARP plays a crucial role in cancer pathology, as the tumor cells highly depend on these enzymes for their DNA repair. Inhibiting these enzymes prevents the further growth of cancerous cells.

PARP enzyme inhibitors are currently gaining huge traction in the cancer therapeutics market. There are several drugs approved and many are in clinical development. The approved drugs include Olaparib, Rucaparib, Niraparib, and Talazoparib. These drugs are used in cancers of the breast, prostate, ovaries, pancreas, etc. Since their approval, the sales of these drugs have been growing at a faster pace. The below graph represents the sales of the top 2 selling PARP enzyme inhibitors Lynparza, and Zejula from their respective launch years. Lynparza has seen significant growth in sales from 2015 to 2023, with the highest CAGR of 52.9%.

Geographical Analysis

North America is expected to hold a significant share of the Enzyme inhibitor market.

North America is estimated to hold the highest market share throughout the forecast period, owing to factors like highly regulated and well-developed healthcare infrastructure, and the higher prevalence of chronic conditions.

For instance, as per the research article by the Centers for Disease Control and Prevention (CDC) published in February 2024, in the U.S., nearly 129 million people have at least 1 chronic disease such as heart disease, cancer, diabetes, obesity, and hypertension. CDC has stated that the prevalence of chronic diseases has been rising steadily for the past 2 decades, and is expected to rise with the same trend in the future.

Moreover, recent statistics published by the CDC in October 2024, have stated that one-half the U.S. adult population is hypertensive and more than one-half (51.2%) of these patients are taking medication to lower their blood pressure. The overall prevalence was 47.7% during the study period of August 2021 to August 2023. As per the American Heart Association, Inc. projections, nearly 60% of U.S. adults will be affected by heart disease and stroke by 2050, and hypertension is the leading cause of this high prevalence risk.

With the alarming rise in chronic conditions, and availability of availability of advanced enzyme inhibitors, strong presence of market players and their innovations, the North America region is considered dominating in the global enzyme inhibitors market.

Competitive Landscape

The major global players in the Enzyme inhibitor market are Pfizer Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Sanofi, AstraZeneca, Gilead Sciences, Inc., and Eli Lilly and Company. among others.

Emerging Players

The emerging players in the Enzyme inhibitor market include Shionogi Inc., Mission Therapeutics, and Corvus Pharmaceuticals among others.

Key Developments

• In July 2024, the U.S. Food and Drugs Administration (FDA) approved ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE is a phosphodiesterase 4 (PDE4) inhibitor developed by Arcutis Biotherapeutics, Inc.
• In June 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) provided accelerated approval for Augtyro (repotrectinib) a novel tyrosine kinase inhibitor for the treatment of patients with NTRK-positive locally advanced or metastatic solid tumors.
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and Enzyme Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Enzyme Type Performance & Market Positioning: Analyzes Enzyme Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-enzyme-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Enzyme Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance Enzyme Type safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Enzyme inhibitor market report would provide approximately 62 tables, 70 figures, and 250 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Enzyme Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of chronic diseases
    • 4.1.1.2. Expanding therapeutic applications
  • 4.1.2. Restraints
    • 4.1.2.1. Market saturation and high generic and brand competition
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Epidemiology
• 5.6. Patent Analysis
• 5.7. Regulatory Analysis

6. By Enzyme Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 6.1.2. Market Attractiveness Index, By Enzyme Type
• 6.2. Angiotensin Converting Enzyme (ACE) Inhibitors*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Cyclooxygenase (COX) Inhibitors
• 6.4. proton Pump Inhibitors
• 6.5. Protease Inhibitors
• 6.6. Beta-lactamase Inhibitors
• 6.7. HMG-CoA Reductase Inhibitors
• 6.8. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• 6.9. Phosphodiesterase (PDE) Inhibitors
• 6.10. Tyrosine Kinase Inhibitors
• 6.11. Monoamine Oxidase (MAO) Inhibitors
• 6.12. Acetylcholinesterase (AChE) Inhibitors
• 6.13. Poly (ADP-ribose) Polymerase (PARP) Inhibitors
• 6.14. Others

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Anti-Inflammatory Drugs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Anticancer
• 7.4. Antibiotics
• 7.5. Antiviral
• 7.6. Antihypertensive
• 7.7. Antidiabetic
• 7.8. Gastrointestinal Drugs
• 7.9. Cardiovascular Drugs
• 7.10. Neurological Drugs
• 7.11. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Enzyme Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Enzyme Type Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Johnson & Johnson Services, Inc.
• 11.3. Merck & Co., Inc.
• 11.4. F. Hoffmann-La Roche Ltd
• 11.5. Novartis AG
• 11.6. AbbVie Inc.
• 11.7. Sanofi
• 11.8. AstraZeneca
• 11.9. Gilead Sciences, Inc.
• 11.10. Eli Lilly and Company.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us